Posted 25th February 2020 by Joshua Sewell
As we look at the current and future market demands for cannabinoid ingredients, large consumer buyers are focused on purity, consistency and stability of supply. For a host of reasons, cannabinoid suppliers will find it extraordinarily difficult to meet this demand with plant-based production systems.
Posted 21st February 2020 by Joshua Sewell
The cannabis industry faces a systemic problem where the legal nomenclature used to distinguish varietals of Cannabis Sativa is known to be unrelated to the genetic identity of the plant.1 Cannabis plants being bought and sold under any specific trade name can be genetically unrelated and may not even have a shared cultivation history.
Posted 14th February 2020 by Joshua Sewell
Medicinal cannabis was legalised in the UK in November 2018, yet there have been fewer than ten new prescriptions made through the NHS. Most of the prescriptions made have been private, and are financially out of reach for most patients, costing up to £2000 per month.